CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Precipio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Precipio Inc
12325 Emmet St
Phone: (203) 787-7888p:203 787-7888 OMAHA, NE  68164-4243  United States Ticker: PRPOPRPO
Business Summary
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes-YesYes

Industries
SIC Code Description
3826 Laboratory analytical instruments

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Richard A.Sandberg 80 3/1/2021 12/1/2019
Chief Executive Officer, Founder, Director IlanDanieli 51 6/29/2017 6/28/2017
Interim Chief Financial Officer MatthewGage 56 3/21/2022 3/21/2022
7 additional Officers and Directors records available in full report.

Business Names
Business Name
CB4Cancer, LLC
Precipio Diagnostics, LLC
Precipio SPV, Inc.
PRPO
TBIO
TBIOD

General Information
Number of Employees: 51 (As of 3/1/2024)
Outstanding Shares: 1,430,292 (As of 3/24/2024)
Shareholders: 34
Stock Exchange: NASD
Federal Tax Id: 911789357
Fax Number: (302) 655-5049
Email Address: investorrelations@transgenomic.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024